Cardiol Therapeutics to Advance CardiolRx into a Late-Stage Trial in Patients with Recurrent Pericarditis
MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 blocker therapy (rilonacept or anakinra) and is expected to run